Histone deacetylase inhibitors (HDACi) had emerged as promising drugs in leukaemia, but their toxicity due to lack of specificity limited their use. Therefore, there is a need to elucidate the role of HDACs in specific settings. The study of HDAC expression in childhood leukaemia could help to choose more specific HDACi for selected candidates in a personalized approach. We analysed HDAC1-11, SIRT1, SIRT7, MEF2C and MEF2D mRNA expression in 211 paediatric patients diagnosed with acute leukaemia. There was a global overexpression of HDACs, while specific HDACs correlated with clinical and biological features, and some even predicted outcome. Thus, some HDAC and MEF2C profiles probably reflected the lineage and the maturation of the blasts and some profiles identified specific oncogenic pathways active in the leukaemic cells. Specifically, we identified a distinctive signature for patients with KMT2A (MLL) rearrangement, with high HDAC9 and MEF2D expression, regardless of age, KMT2A partner and lineage. Moreover, we observed an adverse prognostic value of HDAC9 overexpression, regardless of KMT2A rearrangement. Our results provide useful knowledge on the complex picture of HDAC expression in childhood leukaemia and support the directed use of specific HDACi to selected paediatric patients with acute leukaemia.
Recruitment of chromatin-modifying enzymes by oncogenic fusion proteins and altered expression of chromatin regulators are mediating steps in leukaemogenesis, thus making epigenetic therapies suitable for leukaemia patients (Bolden et al, 2006; Haberland et al, 2009; Chrun et al, 2017) . Histone deacetylases (HDACs) act as transcriptional corepressors by deacetylating histones, leading to a closed chromatin status, and by regulating the activity of non-histone proteins (Barneda-Zahonero & Parra, 2012; Chrun et al, 2017) . The HDAC superfamily is composed of different isoforms that, according to their structure (substrate specificity, enzymatic mechanism, subcellular localization and tissue-specific expression), can be grouped in four classes: class I (HDAC1, 2, 3 and 8), class II (IIa, comprising HDAC4, 5, 7, 9;  class IIb: HDAC6 and 10), class III (sirtuins or SIR, for Silent Information Regulators: SIRT1, 2, 3, 4, 5, 6 and 7) and class IV (HDAC11). Class I HDAC are ubiquitously expressed in all tissues and are found as part of multi-protein complexes recruited to target genes to mediate repression. Class IIa are expressed in a tissue-specific manner and are involved in differentiation and development. Sirtuins are widely expressed and have a broad range of functions, such as DNA repair, regulation of oxidative stress, metabolism and aging. The function of HDAC11, the only member of class IV, is less known, but it seems to be essential for normal haematopoietic differentiation and may be associated with immune system response (Barneda-Zahonero & Parra, 2012; Sahakian et al, 2017) . HDACs are involved in apoptosis, senescence, differentiation and angiogenesis, and have a role in the maintenance and maturation of haematopoietic precursors (Ceccacci & Minucci, 2016) .
When overexpressed, HDACs may behave as oncogenes themselves or repress tumour-suppressive pathways (Ceccacci & Minucci, 2016) . It has been reported that there is a global overexpression of HDACs in several haematological malignancies, correlating with proliferation and survival (Haery et al, 2015) . Subsequently, different HDAC inhibitors (HDACi) are currently in clinical trials for paediatric acute leukaemia (i.e. NCT02419755, NCT02518750, NCT02676323 for KMT2A-rearranged leukaemias, T-ALL and AML, respectively), and other haematological malignancies (reviewed in Ahmadzadeh et al, 2015; Ceccacci & Minucci, 2016; Eckschlager et al, 2017; Zhang et al, 2015; Haery et al, 2015) . HDACi restore the epigenetic balance in neoplastic cells and promote their apoptosis through different mechanisms that include promotion of DNA damage, inhibition of DNA repair and regulation of apoptosis (Bolden et al, 2006; Bose et al, 2014; Eckschlager et al, 2017) .
However, despite promising preclinical work, there are concerns both in terms of efficacy and safety, with secondary non-negligible toxicity (mainly fatigue, diarrhoea, bone marrow toxicity, etc.) (Ceccacci & Minucci, 2016) . To explain the differences between the clinical results and those expected from preclinical studies, one should consider that the mechanism of action of these inhibitors is not fully understood and that their effect may be different depending on the specific type of cancer, cellular context, specificity of the HDACi tested (pan-inhibitors vs. isoform-specific HDACi) and their dosage. Thus, the lack of specificity of HDAC inhibition makes it difficult to predict the biological effects, including toxicities, limiting their use either alone or in combination with chemotherapy. To overcome this issue, more selective (class-selective or isoform-specific) HDACi have recently been developed, aimed at achieving a better outcome with less toxicity (Balasubramanian et al, 2009) .
Acute leukaemia is the most frequent cancer in childhood and the primary cause of paediatric mortality related to cancer Pui et al, 2015) . Although a striking improvement in the outcome of paediatric patients with acute leukaemia has been achieved in the last years, there is still a relevant proportion of patients who will relapse, even amongst those cases stratified in the low-risk group at diagnosis. On the other hand, survivors may suffer severe short-and long-term therapy-related side effects (Raetz & Bhatla, 2012; Gatta et al, 2013; Ward et al, 2014) . Therefore, there is a need to find less toxic, more specific and personalized therapies for childhood leukaemia.
Although monotherapy with HDACi is unlikely to succeed, they could be useful for designing less toxic combination therapies; in this sense, as HDAC's roles are progressively elucidated in specific neoplastic diseases, different approaches combining HDACi with cytotoxic chemotherapy or other novel targeted therapies are being tested (Bose et al, 2014) . However, very few studies have addressed the HDAC expression in paediatric acute leukaemias (Moreno et al, 2010; Gruhn et al, 2013; Tao et al, 2013) .
This study aimed to analyse the expression of HDAC genes and some of their targets and regulators, i.e., certain members of the Myocyte Enhancer Factor 2 (MEF2) family, in a series of paediatric patients with acute leukaemia to address: (1) possible specific profiles of HDAC expression in different subtypes of leukaemia and (2) whether abnormal HDAC expression could have a prognostic impact in our patients. Our final goal was to obtain data to better understand the correlation between HDAC expression and clinicobiological features in childhood leukaemia, to tailor therapy for each subgroup of patients.
Methods and materials
We retrospectively analysed 211 patients aged 0-18 years, diagnosed with de-novo acute leukaemia from 2003 to 2017 in Hospital Sant Joan de D eu, with available biological sample. Our cohort included 134 patients with precursor B cell acute lymphoblastic leukaemia (BCP-ALL), 33 with T cell acute lymphoblastic leukaemia (T-ALL) and 44 with acute myeloid leukaemia (AML), with the main cytogenetic subtypes being represented. The clinical and biological characteristics of the patients are described in Supporting Information. The quantification of HDAC1, 2, 3, 4, 5, 6, 7, 8, 9 , 10 and 11, SIRT1, SIRT7, MEF2C and MEF2D mRNA was performed by real-time polymerase chain reaction (PCR) using an ABI7500 Real-Time PCR System (Applied Biosystems, Foster City, CA), according to the manufacturer's instructions. Relative quantification was calculated with the 2 ÀDDCt method, using b-glucuronidase (GUSB) as endogenous gene. A pool of RNA extracted from the bone marrow of 11 non-neoplastic patients was used as controls. We also determined the HDAC family, MEF2C and MEF2D 
Results

Global HDAC expression in normal haematopoietic cells and in leukaemia patients
We first analysed the expression of HDACs in different subsets of normal haematopoietic cells: bone marrow CD34 + cells, peripheral blood mature CD19
+ lymphocytes and pan-T cells (Fig S1) . In 211 leukaemic patients, we observed a global overexpression of HDACs, MEF2C, and MEF2D genes, except for HDAC1, HDAC3, HDAC10, and SIRT7, whose median expression level was around or below that of the controls (Fig 1) . All cases showed homogeneous expression of class I HDAC1, HDAC2 and HDAC3, in contrast to the more heterogeneous expression of other HDAC isoforms. Nearly all leukaemic patients expressed HDAC1, HDAC2, and HDAC3, while some patients did not express some HDACs. Class III SIRT1 and SIRT7 were expressed in almost all patients. Both MEF2C and MEF2D genes were highly expressed, with MEF2C showing the highest median expression in leukaemic patients, as compared to the non-neoplastic samples.
There is a significant correlation between the expression of HDACs, MEF2C, and MEF2D
Both the whole cohort of patients, and when analysed separately according to lineage, showed a significant positive Spearman's correlation among class I HDACs, which was very strong between HDAC1 and HDAC3 ( Fig S2) . There was also a significant direct correlation among class II members HDACs, especially between HDAC4 and HDAC5, and between class IIa and class IIb HDACs (HDAC4, HDAC5, and HDAC7 correlated to HDAC6 and HDAC10). In turn, MEF2C and MEF2D were strongly correlated with each other. In contrast, some HDACs had different correlation profiles depending on the lineage of the leukaemia. Thus, in BCP-ALL and AML, HDAC9 correlated directly with SIRT1, MEF2C and MEF2D. In T-ALL patients, although the number of samples expressing MEF2 genes was very low, we saw a negative correlation between these genes and some HDACs. Class III SIRT1 and SIRT7, and class IV HDAC11 were more heterogeneous and differed according to the lineage of the leukaemia.
Correlation of HDACs, MEF2C and MEF2D expression with clinical and biological variables
We observed a lower expression of HDAC3 in males (P = 0Á015). Regarding age, high MEF2D levels had a trend to correlate with lower age (P = 0Á056), and HDAC9 expression tended toward higher levels in infants and in patients >10 years, compared to 1-to 9-year-old patients (P = 0Á057). A lower expression of HDAC1 and HDAC3 correlated with hyperleucocytosis above 50 9 10 9 /l (P = 0Á017
and P = 0Á029, respectively). Those patients with infiltration of the central nervous system (CNS-3), presented with lower HDAC2 levels, although this was not significant (P = 0Á052). Interestingly, we observed different HDAC expression according to the lineage of the leukaemia (see below and Fig S3) .
Different expression of HDACs, MEF2C, and MEF2D in BCP-ALL patients according to cytogenetics
In the 134 BCP-ALL patients analysed, we observed expression of class I HDAC1, HDAC2 and HDAC3, as well as SIRT1, SIRT7, MEF2C and MEF2D in almost all samples.
Patients with BCP-ALL showed significantly higher expression of HDAC6 and MEF2C when compared to T-ALL and AML patients (P = 0Á005 and P < 0Á001, respectively). Globally, the BCP-ALL profile for HDAC classes I, II and IV was closer to the normal CD34 + cells than to the mature CD19 + cells ( Fig S4) . Regarding the absence of expression of certain genes, while mature B cells were characterized by the lack of expression of HDAC5 only, about 70% of BCP-ALL patients did not express HDAC11. In addition, HDAC4 and HDAC5 were absent in half of our patients, and HDAC6, HDAC7, HDAC8, HDAC9 and HDAC10 expression was not detected in a lower percentage of patients (5-20%). Interestingly, patients simultaneously lacked several HDACs, both from the same class or from different classes. We analysed if the lack of expression of a certain HDAC correlated with any clinical or biological variable, but only observed that the absence of expression of HDAC8 in BCP-ALL patients correlated with high minimal residual disease (MRD) levels at day 15 of induction treatment (MRD > 10%, P = 0Á03).
Regarding the correlation between the expressed genes and clinical and biological variables in BCP-ALL patients, we found a higher HDAC5 expression in males (P = 0Á021). Higher expression of HDAC9, HDAC11, SIRT7 and MEF2D correlated with hyperleucocytosis (P = 0Á031, P = 0Á024, P = 0Á014 and P = 0Á005, respectively). Those patients with a pro-B phenotype (n = 9) had significantly lower age (infants, P < 0Á001), hyperleucocytosis (P = 0Á002) and were associated with KMT2A (lysine methyltransferase 2A, previously termed MLL) rearrangement (P < 0Á001), but we found no association of this phenotype with specific HDAC expression. Noticeably, HDAC expression was different according to the cytogenetic subtypes ( Fig S5) . Thus, nearly all patients with KMT2A rearrangement and patients with translocation t(1;19)/TCF3-PBX1 fusion gene expressed all genes, whereas patients included in other categories lacked expression of class II and IV HDAC genes: absence of HDAC11 was particularly frequent in patients with t(9;22)/BCR-ABL1 and patients with t(12;21)/ETV6-RUNX1, where it was absent in more than 80% of the cases. Interestingly, a specific profile was identified for patients with BCP-ALL and KMT2A rearrangement: they expressed, in all but one case, HDAC4 (P = 0Á009), and had a significantly higher expression of HDAC9, SIRT7 and MEF2D than other BCP-ALL subtypes (P = 0Á033, P = 0Á039, and P = 0Á016, respectively).
Different expression of HDACs, MEF2C, and MEF2D in T-ALL patients
Similarly to BCP-ALL, nearly all the 33 T-ALL patients expressed HDAC1, HDAC2, HDAC3, SIRT1, SIRT7, MEF2C and MEF2D (Fig S3) . Patients with T-ALL had the highest levels of SIRT1, as compared to BCP-ALL and AML cases (P = 0Á036). In contrast to mature Pan-T cells, most patients expressed HDAC4 to HDAC9 and MEF2C at different levels. Males with T-ALL presented higher HDAC10 levels (P = 0Á005). Of note, we found an association between high HDAC4 expression and a poor prednisone response at day +8 of induction treatment, although not at a significant level (P = 0Á053). T-ALL patients with NOTCH1/FBXW7 mutations (n = 14), presented some differences with non-mutated cases in HDAC and MEF2C expression (Fig S6) . Thus, mutated NOTCH1/FBXW7 patients more frequently lacked HDAC4, HDAC5, HDAC6, HDAC9, HDAC11 and MEF2C, resembling their normal mature counterpart. All patients with absent expression of MEF2C were NOTCH1/FBXW7 mutated, while all but one patient with high MEF2C expression were wild-type for NOTCH1/FBXW7 screening; however, the very low number of patients precluded a conclusion regarding statistical significance. The only patient who 
Different expression of HDACs, MEF2C, and MEF2D in AML patients
In our 44 AML patients, as in other lineages, the analysed class I and III HDACs, MEF2C and MEF2D genes were expressed in almost all samples. Of note, class I HDAC1, HDAC3, HDAC8 and HDAC7 were significantly underexpressed in AML cases compared to lymphoid leukaemias (P < 0Á001, P = 0Á008, P = 0Á001 and P = 0Á001, respectively; Fig S3) . We observed that low levels of HDAC1 and SIRT1, and absence of HDAC10 and/or HDAC7 was associated with hyperleucocytosis >50x10 9 /l (P = 0Á028, P = 0Á008, P < 0Á001
and P = 0Á034, respectively). Low levels of SIRT1 also correlated significantly with CNS infiltration (CNS-3) (P = 0Á048). Notably, as in BCP-ALL patients, higher HDAC9 and MEF2D expression was associated with the presence of KMT2A rearrangement (P = 0Á034 and P = 0Á042, respectively).
Patients with KMT2A rearrangement overexpressed HDAC9 and MEF2D, regardless the age and the lineage of the leukaemia
In the whole patient cohort, a high expression of HDAC9 and MEF2D was significantly associated with the presence of KMT2A rearrangement (P = 0Á005 and P = 0Á034, respectively), in both infant and paediatric patients. As KMT2A rearrangements were significantly more frequent in infants (P < 0Á001), we analysed HDACs, MEF2C and MEF2D expression in different groups according to age (infants vs. paediatrics) and the presence of the KMT2A rearrangement (Fig 2) . KMT2A-rearranged cases included different translocations with different partners (Table S1 ). Interestingly, KMT2A rearrangements presented a distinctive signature that was independent of age, lineage and KMT2A-partner, characterized by overexpression of HDAC9 and MEF2D genes.
HDAC expression may impact on outcome of paediatric patients with acute leukaemia
After a median follow-up of 4Á8 years (range, 0Á1-16Á0 years), 25 of the whole cohort of patients had died. The overall survival (OS) and event-free survival (EFS) varied significantly according to the lineage of the leukaemia, as expected (Table S1 ). Log rank tests were first performed to assess outcome in the BCP-ALL subgroup (n = 134). CNS infiltration (CNS-3) predicted a worse OS (P = 0Á019). Patients aged 1-9 years had better OS than infants or older patients (P = 0Á046). Among the genes analysed, only low HDAC2 expression (defined with a cut-off at 3Á29; around the median, percentile 50, p50), high HDAC9 (cut-off 3Á62; around p65) and high SIRT1 (cut-off 4Á08; around p70), negatively impacted significantly on OS (P = 0Á008, P = 0Á007 and P = 0Á027, respectively). Different clinical and biological factors were predictive of EFS: age (both categorized as infants vs. noninfants and as 3 groups: infants vs. 1-9 years vs. 10 years and older), CNS infiltration, cytogenetic subgroup, the presence of KMT2A rearrangement and MRD levels after induction (>0Á01% MRD, as assessed by flow cytometry). Again, low HDAC2 and high HDAC9 expression predicted a worse EFS (P = 0Á002 and P < 0Á001, respectively; Fig 3) . In the Cox model for multivariate analysis, low HDAC2 and high HDAC9 expression remained as independent prognostic factors for EFS (hazard ratio [HR] 0Á12, 95% confidence interval [CI] 0Á03-0Á50, P = 0Á003, and HR 42Á48, 95%CI 3Á80-473Á97, P = 0Á002, respectively).
We found no significant factors predictive for OS in T-ALL patients (n = 33). However, hyperleucocytosis > 100 9 10 9 /l and positive MRD after induction (>0Á01%, as assessed by flow cytometry), were adverse prognostic factors for EFS (log rank test, P = 0Á04 and P = 0Á004, respectively). Probably related to the sample size, we found no significant predictive factors in the multivariate analysis. In the subgroup of AML patients (n = 44), patients with high HDACs expression had a worse outcome. High HDAC9 expression correlated with a worse OS (P = 0Á011). Although the number of patients expressing HDAC5 was low (n = 18), we saw a worse OS and EFS in patients with high levels of this gene, that remained significant in the Cox model multivariate analysis for OS (HR 10Á92, 95%CI 1Á16-103Á29, P = 0Á034). As for EFS, we found that hyperleucocytosis >50 9 10 9 /l, the genetic subtype (grouped as follows: acute promyelocytic and core-binding factor leukaemias vs. KMT2A-rearranged leukaemias vs. KMT2A wild-type cases) and high HDAC8 expression (Fig 4) had a significant impact (P = 0Á027, P = 0Á002 and P = 0Á015, respectively). High levels of HDAC1 and high HDAC9 expression showed a trend to lower EFS (P = 0Á052 and P = 0Á074, respectively).
Discussion
Hypoacetylation has been recurrently described in cancer and overexpression of HDACs has been reported in leukaemia (Ropero & Esteller, 2007; Haberland et al, 2009; Ceccacci & Minucci, 2016) . Hence, more than 40 HDACi have been included in clinical trials (Bose et al, 2014; West & Johnstone, 2014; Ahmadzadeh et al, 2015; Haery et al, 2015; Ceccacci & Minucci, 2016; Chrun et al, 2017) , but the toxicity found in patients hampered their use in clinical practice and the use of more specific HDACi has been proposed (Subramanian et al, 2010; Ceccacci & Minucci, 2016) . Thus, a better knowledge of HDAC expression in specific settings would help to design the best therapeutic approach in a tailored manner. However, only a few studies (Moreno et al, 2010; Gruhn et al, 2013; Tao et al, 2013) , with a much smaller number of patients, have partially addressed the expression of specific HDACs classes in childhood leukaemia, and no N. Vega-Garc ıa et al global picture has been described to date. We analysed a large consecutive series of patients including all leukaemic lineages and found that some HDACs correlated with specific clinical and biological features, and some even predicted outcome. Specifically, we found an HDAC profile that correlated with KMT2A rearrangement, regardless of age, KMT2A-partner and lineage. Other HDAC and MEF2C profiles were probably reflecting the lineage and the maturation of the blasts and, interestingly, some indicated specific oncogenic pathways active in the leukaemic cells. Expression levels of HDACs, MEF2C and MEF2D genes according to age and KMT2A gene rearrangements. Relative quantification was calculated with the 2 ÀDDCt method and a pool of non-neoplastic samples was used as controls (X-axis). Dashed lines represent the median value of the samples. The log 2 normalized gene expression is depicted for infant (grey dots) and paediatric (orange dots) patients. To assess the different profile according to age and KMT2A rearrangement, we analysed them separately: light grey dots corresponds to infants with no KMT2A rearrangement, while dark grey dots depict KMT2A-rearranged infants; light orange dots are paediatric patients with wild-type KMT2A, and dark orange dots show paediatric patients with KMT2A rearrangement. Outliers are represented in scale at the top of the graph and patients who did not express a determined gene are represented out of the limits of Y-axis (bottom of the graph, not to scale). 2a) Expression levels of HDACs, MEF2C and MEF2D genes according to age and KMT2A rearrangement. 2b) Enlarged view of HDAC9 and MEF2D genes according to age and KMT2A rearrangement. Not previously reported, we observed that some HDACs were constantly expressed in all patients, whereas other HDAC isoforms seemed to be non-essential for blasts and were absent. Interestingly, nearly all patients of all lineages expressed class I HDACs, especially HDAC1, HDAC2 and HDAC3 and, to a lesser extent, HDAC8. These are the nuclear isoforms with HDAC function that are ubiquitously expressed in all tissues. HDAC1, HDAC2 and HDAC3 are essential for haematopoietic stem cell (HSC) maintenance and self-renewal properties (Barneda-Zahonero & Parra, 2012; Haery et al, 2015; Liu et al, 2017) . Therefore, it seems comprehensible that all our patients, independently of the lineage of the leukaemia, constantly expressed these class I HDACs, and also very homogeneously, as shown in Fig 1. Interestingly, we observed a significant direct correlation among class I HDACs, especially between HDAC1 and HDAC3. Although a functional redundancy among class I HDACs has been suggested, each member has unique roles in the control of specific gene expression programs (Haberland et al, 2009 ). HDAC1 and HDAC2 are involved in many cellular processes, such as proliferation, cell cycle and apoptosis, while HDAC3 also plays a role in DNA damage response (Barneda-Zahonero & Parra, 2012) . Thus, HDAC1, HDAC2 and HDAC3 seem to be equally indispensable, highlighting the important function of these class I HDACs in normal and leukaemic cells. HDAC8 was expressed in our patients in a more heterogeneous way, but we observed a direct correlation with HDAC2 levels, especially in patients with BCP-ALL and T-ALL. HDAC8 has not been described as a member of any protein complex and its expression is thought to be more cancer-type specific (Barneda-Zahonero & Parra, 2012) .
Regarding the levels of expression, we observed lower levels of HDAC1 and overexpression of HDAC2 and HDAC8 when compared to bone marrow non-neoplastic samples. We also confirmed the profile previously reported both in smaller cohorts of paediatric patients with acute leukaemia (Moreno et al, 2010; Gruhn et al, 2013) and in several types of cancer (Chrun et al, 2017) . In contrast, class IIa HDACs expression was quite more heterogeneous and differed according to the lineage of the leukaemia. Our findings are in line with a heterogeneous expression reported in previous studies (Moreno et al, 2010) . Class III SIRT1 and SIRT7 were more heterogeneously expressed in most of our patients, and we observed an overall overexpression of SIRT1, especially in T-ALL patients. Sirtuins seem to play a double-edged sword role in cancer, being reported as pro-oncogenes and as tumour suppressors (Barneda-Zahonero & Parra, 2012) . SIRT1 plays an important role in the pathogenesis of solid tumours and leukaemias and has also been involved in drug resistance, by regulating the acetylation of several transcription factors, such as TP53, C-MYC, N-MYC and NF-jB, and others (Ahmadzadeh et al, 2015) . Thus, in chronic myeloid leukaemia samples, the inhibition of SIRT1 by HDACi led to TP53 acetylation and increased apoptosis in leukaemia stem cells (Ahmadzadeh et al, 2015; Liu et al, 2017) . Overexpression of SIRT1 has been described in adult patients with AML (Bradbury et al, 2005) and Li et al (2014) proposed the combination of SIRT1 inhibition plus tyrosine kinase inhibitors to overcome drug resistance in FLT3-internal tandem duplication AML stem cells by acetylating C-MYC. Overall, all patients presented an HDAC profile more similar to that of normal CD34
+ cells than to their mature counterpart, especially T-ALL patients. Thus, global overexpression of some HDACs could be related to the immature and stemness features of the leukaemic cells. However, in addition to common findings in our whole cohort of patients, some HDACs profiles were associated with the lineage of the leukaemia, exposing HDACs different roles in specific cellular contexts. In the BCP-ALL cohort (n = 134), we sought to confirm a differential expression of HDAC7 expression in pro-B patients, as described by Barneda-Zahonero et al (2015) , but the number of pro-B cases analysed in our series was low and we did not observe significant differences. Importantly, HDAC expression was different according to cytogenetic subtype (Fig S5) . Thus, both KMT2A-rearranged patients and those harbouring t(1;19)/TCF3-PBX1 expressed all HDACs in nearly all samples, in contrast to other BCP-ALL subtypes, in which the expression was more heterogeneous and a high percentage of patients lacked the expression of several HDACs. This could be related to a specific epigenetic landscape as determined by the genetic abnormalities of each leukaemic subtype. Importantly, we observed a specific profile of KMT2A-rearranged BCP-ALL patients, who expressed significantly higher levels of HDAC9, SIRT7 and MEF2D. Of note, we also observed a significant correlation between high HDAC9 and MEF2D expression in KMT2A-rearranged AML patients, and this was also true in both infants and older patients (Fig 2) . Hence, we found a distinctive signature for KMT2A-rearranged patients, regardless of age, the KMT2A-partner and phenotype. Other than KMT2A-rearrangements, overexpression of HDAC9 and MEF2D could be due to different abnormalities: very recently, a new subtype of BCP-ALL characterized by MEF2D-rearrangements with different partners (BCL9, CSF1R, DAZAP1, HNRNPUL1, and SS18) has been described Suzuki et al, 2016) . Interestingly, such MEF2D-rearrangements presented in older patients with a low CD10 expression, showed a specific gene expression signature with overexpression of HDAC9 and were sensitive to HDACi . We also observed significantly high expression of MEF2C in BCP-ALL and AML and in some T-ALL cases. MEF2 proteins are targets of class II HDACs and regulate different developmental programs Pon & Marra, 2016) . MEF2C is differentially expressed in various stages of haematopoietic development and it may be involved in conferring stem cell-like properties. MEF2C is highly abundant in HSC, common lymphoid progenitors and common myeloid progenitors and decreases during B-lymphoid and myeloid maturation, but it is absent in T cells . In concordance with that, we did not find MEF2C expression in normal mature T cells. However, the high ectopic MEF2C expression has been described in KMT2A-rearranged leukaemias (Krivtsov et al, 2006) , AML and two partially overlapping immature T-ALL subtypes: the so-called early T cell precursor leukaemia (ETP-ALL) (Coustan-Smith et al, 2009; Cant e-Barrett et al, 2014) and in a recently described T-ALL subgroup defined by high MEF2C expression (Homminga et al, 2011) . ETP-ALL is characterized by presenting an immature immunophenotype, expression of myeloid markers and lower frequencies of NOTCH1 mutations than more differentiated T-ALL patients. Instead, ETP-ALL patients harbour a mutational landscape similar to AML patients (Zhang et al, 2012) . In this regard, MEF2C has been reported to antagonize the NOTCH1 signalling activity. Therefore, ectopic expression of MEF2C would play a role as a driving oncogene in myeloid or early T cell precursors, resulting in AML or ETP-ALL, respectively . Of note, in our cohort, all but one T-ALL patients with NOTCH1/FBXW7 mutations lacked expression of MEF2C, and the only patient with high MEF2C expression and mutations in NOTCH1/FBXW7 had an immature phenotype ( Fig  S6) . However, other studies did not observe differences in the occurrence of NOTCH1 pathway activating events between immature/ETP-like and other T-ALL patients defined by gene expression profiling (Zuurbier et al, 2014; Colomer-Lahiguera et al, 2017) . These differences could be due either to the different selection criteria or the different numbers of patients analysed, as the number of T-ALL patients expressing MEF2C in our series was rather low. In AML, high MEF2C expression has been associated with 11q23 abnormalities (Krivtsov et al, 2006; Laszlo et al, 2015) , monosomal karyotypes, adverse-risk disease features and poor outcome (Laszlo et al, 2015) . In KMT2A-MLLT3 and KMT2A-MLLT1 models, MEF2C could have a cooperative oncogenic role, enhancing colony formation and regulating cell migration and invasiveness (Krivtsov et al, 2006; Schwieger et al, 2009) .
Regarding outcome, we confirmed the previously described worse prognosis of high HDAC9 expression in BCP-ALL patients (Moreno et al, 2010) , but, in contrast to previous studies (Gruhn et al, 2013) , we found that lower HDAC2 expression correlated with worse OS and EFS. High or heterogeneous levels of HDAC2 have been described in several cancers, and suppression of HDAC2 with class I HDACi has resulted in inhibition of proliferation and increased apoptosis of tumour cells (Barneda-Zahonero & Parra, 2012; Chrun et al, 2017) . As we have only looked at mRNA levels and some post-translational modifications for HDAC2 have been reported (Kr€ amer et al, 2003) , the prognostic value of HDAC2 expression should be further explored. In general, our AML patients with high HDACs expression had a worse outcome, and again high HDAC9 expression significantly correlated with a worse OS, and had a trend to a worse EFS. The impact of HDAC9 overexpression on outcome may be partially explained by the fact that HDAC9 may act as a surrogate of KMT2A rearrangements, both in BCP-ALL and in AML. However, the negative impact of high HDAC9 levels was also seen in BCP-ALL KMT2A-wild-type patients, suggesting a possible prognostic impact of other recently described genetic abnormalities like MEF2D rearrangements, as aforementioned Suzuki et al, 2016) . HDAC9 overexpression has been associated with dismal outcome in other neoplasias, such as breast cancer and medulloblastoma (Milde et al, 2010; Lapierre et al, 2016) . However, the specific role of HDAC9 in leukaemia biology and the mechanisms underlying the overexpression and the functional consequences are not fully understood. We discarded mutations in the hot-spot regions in the catalytic domain of HDAC9 as a molecular mechanism leading to enhanced expression (data not shown). Lapierre et al (2016) suggested that the deregulation of HDAC9 expression mainly occurs at the transcriptional level, as evidenced by their run-on experiments and the finding of epigenetic marks in the HDAC9 promoter. As HDAC9 is a direct transcriptional target of MEF2D, deregulation of MEF2D could account for the HDAC9 overexpression. In our study, we found a significant direct correlation between both genes. Interestingly, in breast cancer, the comprehensive signature of the HDAC9 expression revealed deregulated processes, such as cell death and survival, cell movement, cell growth and proliferation, and identified SOX9 and CDKN1A as two important genes mediating HDAC9 effects (Lapierre et al, 2016) . However, these results could be context-dependent and should be confirmed in other neoplasias.
We observed a trend towards significance between high expression of HDAC4 and prednisone-poor response in our T-ALL patients. Similar results had been previously reported (Moreno et al, 2010; Gruhn et al, 2013) . This information could be clinically relevant, as HDAC4 inhibitors could be useful in the high-risk subgroup of patients with T-ALL with poor response to prednisone; therefore, larger series of patients with more robust statistical data are needed to confirm this.
Of note, high HDAC8 levels in AML patients were associated with worse outcome (Fig 4) . HDAC8 is a class I member that deacetylates both histone and non-histone proteins, with TP53 and HOXA5 being among its substrates. In normal haematopoiesis, HDAC8 modulates TP53 activity to ensure HSC maintenance and cell survival under stress (Hua et al, 2017) . In leukaemia, in addition to the modulation of TP53, HDAC8 also associates with the inv(16) fusion protein and other co-repressors to repress several genes, such as CDKN1A (p21), resulting in abnormal haematopoietic cell proliferation (Hua et al, 2017) .
HDACi arose as promising drugs, but their toxicity profile limited their clinical use and suggested that isoform-specific HDACi should be considered, especially for high-risk paediatric leukaemia subtypes (Balasubramanian et al, 2009; Stahl et al, 2016) . Several studies have shown a correlation between the expression of HDACs and the effect of HDACi Suzuki et al, 2016) . The authors demonstrated sensitivity to various pan-HDACi in in vitro and in vivo models with MEF2D-BCL9 leukaemic samples, characterized by HDAC9 overexpression, thus suggesting HDACi as a potential directed treatment in this leukaemia subtype.
In general, KMT2A rearrangements harbour a worse prognosis, especially in infants, in whom the prognosis is dismal (Meyer et al, 2018) . Huge efforts have been made to develop targeted therapies to inhibit KMT2A leukaemias (reviewed in (Steinhilber & Marschalek, 2018) ), including the use of HDACi (Stumpel et al, 2012; Ahmad et al, 2014; Garrido Castro et al, 2018; Steinhilber & Marschalek, 2018) . However, DOT1L inhibitors and other approaches did not accomplish the initial expectations in terms of efficacy and toxicity. In contrast, the use of class I HDACi seems to be especially beneficial, as they inactivate the KMT2A-AFF1 fusion gene while activating the endogenous wild-type MLL (KMT2A) protein (Ahmad et al, 2014; Steinhilber & Marschalek, 2018) . These and our findings support the use of selective class I HDACi for KMT2A and other paediatric leukaemia patients, as a potential therapeutic activity in BCP-ALL has been demonstrated (Stubbs et al, 2015) .
Our studies have some limitations that need to be acknowledged. First, despite being the largest series of patients reported addressing HDACs expression, the incidence of childhood leukaemia is low, and the number of patients in determined subgroups, defined by lineage or molecular abnormalities, was not high enough to reach statistical significance. Therefore, our results must be taken with caution and deserve further confirmation in larger series. Second, we did not confirm our results at a protein level. However, there is some data suggesting that the expression pattern of HDAC transcripts is very similar to that of HDAC proteins in normal and malignant haematopoietic cells, suggesting that the expression of HDACs is regulated primarily at the mRNA level (Wada et al, 2009 ). However, post-translational modifications cannot be ruled out, especially in HDAC2, as previously reported (Kr€ amer et al, 2003) . Finally, we cannot provide a large validation cohort, but we have been able to confirm the prognostic impact of HDAC2 and HDAC9 in two different therapeutic protocols in our BCP-ALL patients, thus reinforcing their value as prognostic biomarkers. On the other hand, it is a strength of our study that we analysed the full HDAC family and MEF2C and MEF2D genes in the largest series of homogeneously treated paediatric patients reported to date, simultaneously including all lineages for the first time. This has allowed us to compare HDACs profiles and gain a full picture of their expression in childhood leukaemia. Furthermore, we could identify a distinctive signature for KMT2A rearrangements and describe the role of some HDACs as prognostic biomarkers.
In conclusion, we have identified a distinctive signature for paediatric patients with KMT2A rearrangements, with high HDAC9 and MEF2D expression, regardless of age, KMT2A partner and lineage of the leukaemia. Moreover, we confirmed previous data on the adverse prognostic value of overexpression of HDAC9 that cannot be explained only by KMT2A rearrangements. Our findings shed some light on the complex picture of HDACs expression in childhood leukaemia and pave the way to more in-depth mechanistic studies. In this sense, it would be very interesting to have a deeper insight of the mechanisms leading to the overexpression of HDACs and their role in leukaemogenesis, issues that have been scarcely studied in leukaemia. Finally, and more importantly, our data support the directed use of selective class I HDACi or even isoformrestricted HDACi or MEF2 inhibition in selected subtypes of paediatric patients with acute leukaemia.
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